Calculators, Algorithms, Drug Interaction CheckersTools
Back To Search Results

Marfan Syndrome

Author: Irim Salik Editor: Prashanth Rawla Updated: 1/23/2023 7:52:05 PM

Introduction

One of the most common inherited disorders affecting connective tissue, Marfan syndrome (MFS), is an autosomal dominant condition with a reported incidence of 1 in 3000 to 5000 individuals.[1][2] The defect is in the FBN1 gene of chromosome 15, which produces fibrillin, a connective tissue protein.[3][4] There is a broad range of clinical severity associated with MFS, ranging from isolated features of MFS to neonatal presentation of severe and rapidly progressive disease involving multiple organ systems.[5] The syndrome is associated with classic ocular, cardiovascular, and musculoskeletal abnormalities, although involvement of the lung, skin, and central nervous system may also occur.[6][7] Decreased life expectancy occurs primarily due to aortic complications, including aortic root dilatation and dissection.[8]

The patients with MFS display multiple deformities of the skeleton, including dolichostenomelia (long limbs compared to trunk), arachnodactyly (abnormally long and thin digits), thoracolumbar scoliosis, and pectus deformities (excavatum and carinatum).[9][10] Aortic regurgitation, dilatation, and aneurysms are most common in the cardiovascular system.[4][11] Mitral valve prolapse can also occur.[12] Ocular findings include lens dislocation, cataracts, myopia, and retinal detachment.[13] The diagnosis of MFS is usually made clinically based on typical abnormalities. Craniofacial characteristics, thumb and wrist signs, severe hindfoot valgus, and pectus carinatum are the physical features with the highest diagnostic yield.[14] There is no specific laboratory test except molecular genetic testing for diagnosing MFS.[15] No specific treatment cures MFS, but specific interventions may improve certain aspects of the syndrome. Medical therapy with beta-blockers and other afterload-reducing agents aims to reduce stress on the aortic valve, mitral valve, and aortic root.[16] Outcome improves with early diagnosis, medical treatment to delay or prevent the progression of aortic dilatation, and timely elective surgery.

Etiology

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Etiology

Although it has an autosomal dominant inheritance, rare case reports have described recessive fibrillin 1 gene (FBN1) mutations.[17] While most individuals with MFS have an affected parent, 25% of patients develop the disease due to a de novo mutation involving the gene (FBN1) encoding the connective tissue protein fibrillin-1.[18][19] FBN1 is a large gene (65 exons) located at chromosome 15q-21.1. Fibrillin-1 is a matrix glycoprotein that is the main constituent of elastic fibers.[20][21] In less than 10% of patients with typical Marfan phenotype, no mutation in FBN1 is identifiable, likely due to complete allele deletion or altered regulation of the FBN1 gene. In patients with atypical presentations reminiscent of MFS, a mutation in a gene encoding for transforming growth factor-beta receptor (TGFBR) may be the cause. Some individuals with TGFBR1 or TGFBR2 mutations have clinical features consistent with MFS, while others have features of 1 of 2 other syndromes: Loeys-Dietz syndrome (LDS) or familial thoracic aortic aneurysm (FTAA) syndrome.[5]

Epidemiology

Approximately one in every 3,000 to 5,000 individuals is affected.[4] The disease occurs worldwide, with no preference for race or gender. It exhibits complete penetrance with variable expression.[22] Twenty-five percent of cases present sporadically due to de novo mutations.[2] MFS is one of the most common single-gene malformation syndromes.

Pathophysiology

The pathophysiology of aortic dilatation in MFS is a complicated process. Fibrillin-1 regulates TGF-beta bioavailability, leading to inflammation, fibrosis, and activation of specific matrix metalloproteinases (MMPs), particularly MMP-2 and MMP-9.[23] Cystic medial degeneration of the aorta occurs when an accumulation of mucopolysaccharide cysts leads to the loss of vascular smooth muscle cells. Aortic wall weakening is due to increased release of MMP, cytokines, chemokines, prostaglandin derivatives, and elastic degradation fragments. In conjunction with decreased collagen, these factors reduce aortic structural integrity and lead to aneurysmal dilatation.[24] Reduced or altered forms of fibrillin-1 can stimulate the release of sequestered TGF-beta and increase its activity.[25] MFS is, therefore, caused by vascular remodeling due to a combination of structural microfibril changes, excess TGF-beta, and overexpression of MMP-2 and MMP-9.[24] The role of TGF-beta in the pathophysiology of MFS has been solidified by the use of the therapeutic angiotensin-converting enzyme inhibitors and angiotensin 2 receptor blockers (ARBs), both proven to decrease TGF-beta activity. Early studies in a mouse model of MFS have shown the utility of a TGF-beta-neutralizing antibody or ARB losartan in treating the disease.[26] Comparatively, mutant mice treated with propranolol only exhibited a moderate reduction in the rate of aortic root dilation. Human studies substantiated that ARB therapy significantly reduced the rate of change in the aortic root diameter compared to beta-blocker therapy alone.[27] Various conditions with pronounced clinical overlap with MFS are caused by primary mutations in genes encoding direct effectors or regulators of TGF-beta signaling, including Loeys-Dietz syndrome (LDS) and Shprintzen-Goldberg syndrome (SGS).

Histopathology

Histologic features of the medial layer of the aortic root in patients with MFS include cystic medial necrosis, fibrosis, and loss of smooth muscle cells.[28][29] Although cystic medial necrosis and the other histologic findings are not specific to MFS, greater elastin fragmentation has been shown in patients with aortic root aneurysms with MFS compared to those without a connective tissue diagnosis.[30]

History and Physical

History and physical for patients with MFS encompass various organ systems. Of primary concern is cardiac pathology. Aortic root disease, leading to aortic regurgitation, aneurysmal dilatation, and dissection, is the primary cause of morbidity and mortality in MFS in up to 60% to 80% of patients.

Revised Criteria for Patients with MFS

  • Aortic root dilatation
  • Family history of aortic root dilatation
  • FBN1 mutation previously associated with aortic root dilatation

Dilatation may also involve other segments of the thoracic aorta, the abdominal aorta, the root of the pulmonary artery, or even the carotid and intracranial arteries. However, this is much less frequent than observed in LDS.

As recommended in the 2010 American College of Cardiology/American Heart Association/American Association for Thoracic Surgery (ACC/AHA/AATS) thoracic aorta guidelines, echocardiography is recommended at initial diagnosis and 6 months to assess the aortic root and ascending aorta in patients with MFS.[31] A 6-month echocardiogram is performed to confirm the stability of the aortic dimension. Nomograms and Z-scores are used to identify aortic dilatation because the normal range for aortic diameter varies with body size and age. Undiagnosed and untreated MFS is often associated with aortic dissection that begins above the coronary ostia and can extend the entire length of the aorta, known as a type 1 dissection in the DeBakey classification. Based on a review from the International Registry of Aortic Dissection (IRAD),[32] MFS causes an aortic dissection in 50% of those under age 40, compared to only 2% of older patients with aortic dissection and no patients over age 70.[33]

Aortic dissection and rupture are preventable in patients with MFS by replacement of the ascending aorta. Prophylactic surgery is recommended when the ascending aorta's diameter at the aortic sinuses' level reaches 5.0 cm. Patients with an aortic diameter of less than 2.75 cm/m2 are considered to be at low risk of dissection, those with 2.75 to 4.24 cm/m2  are at moderate risk, and those with greater than 4.25 cm/m2 are at high risk. A family history of dissection, increased rate of aortic dilation (greater than 2 mm per year), severe aortic valve regurgitation with left ventricular dilation, and relative feasibility of aortic valve-sparing surgery are also indicators for early surgical intervention.[34]

Mitral valve prolapse (MVP) is identified in 40% to 54% of patients with MFS.[35][36] Since it is nonspecific, only 1 point in the systemic score is assigned for MVP.[37] The frequency of MVP in MFS increases with age and is more prevalent in women. Tricuspid valve prolapse may also occur. Patients with MFS and MVP have mild regurgitation (MR).[35] In these patients, the worsening of MR is due to spontaneous rupture of the chordae tendineae or infective endocarditis. Heart failure caused by MVP and MR represents a major source of morbidity and mortality in young children with rapidly progressive MFS. Due to disrupted granular fibers from the proximal aorta to the base of the innominate artery, care should be taken without cross-clamp placement for patients with MFS with MVP.[38] The presence of aortic regurgitation should be taken into account when performing cardioplegia to ensure adequate myocardial protection. Freedom from moderate or greater mitral regurgitation at 5, 10, and 20 years is about 95%, 89%, and 69%, respectively.[39] Patients with MFS may have cardiomyopathy with biventricular enlargement and mild systolic dysfunction.[40] Patients may exhibit proximal ascending aortic dilation, proximal main pulmonary artery dilation, thickening and prolapse of the atrioventricular valves, and mitral annular calcification.

Patients with MFS have excess linear growth of the long bones and joint laxity. Some have reduced joint mobility, particularly of the elbow and digits. Individuals with MFS are taller than the general population.[41] They have disproportionately long extremities compared to the length of the trunk or dolichostenomelia. Patients typically have arachnodactyly with a positive thumb sign where the entire distal phalanx protrudes beyond the ulnar border of a closed fist. Patients also exhibit a positive wrist sign where the top of the thumb covers the whole fingernail of the fifth finger when wrapped around the contralateral wrist. MFS commonly exhibit either pectus carinatum or pectus excavatum. Pes planus, or flatfoot deformity, caused by ligamentous laxity, leads to longer and narrower feet than the average person.[42]

Patients present with diagnostic findings for scoliosis, including a vertical difference of equal to 1.5 cm between the left and right hemithorax ribs and a Cobb angle of at least 20 degrees. If scoliosis is absent, exaggerated kyphotic thoracolumbar spinal curvature can be considered to aid in diagnosing MFS. Radiographic findings of MFS scoliosis are indistinguishable from adolescent idiopathic scoliosis (AIS). Scoliosis associated with MFS is less responsive to a brace; therefore, a brace is only utilized in skeletally immature patients with scoliotic curves less than 25 degrees.[43] Surgery should be considered in patients with curves greater than 45 degrees, although it is associated with higher revision and complication rates than AIS.[7] In a retrospective, case-controlled study by Gjolaj et al.,[44] patients with MFS scoliosis had higher rates of cerebrospinal fluid leaks, an increased likelihood of complications related to implant placement, and more surgical revisions secondary to fixation failure and a spinal fracture. Studies have also reported higher blood loss and longer operative times than in patients with AIS.[45][46] Surgeons must also consider the unique anatomic features of patients with MFS, including narrow pedicles, wide transverse processes, and vertebral scalloping.[9]

An acetabular protrusion, or protrusio acetabuli, can be diagnosed by the medial protrusion of the acetabulum equal to 3 mm beyond the ilio-ischial (Kohler) line. This reflects 1 of the main causes of osteoarthritis in patients with MFS. Degeneration of the hip joint is secondary to ligamentous laxity combined with this bony abnormality. Thakkar et al.[47] noted that hip dislocations are caused by impingement on the deeper acetabulum or ligamentous laxity, and implant failure may be secondary to osteoporosis or osteopenia. Annual ophthalmologic evaluation is recommended for all patients with MFS secondary to ectopia lentis, which occurs in 50% to 80% of patients.[48] It is diagnosed by slit-lamp examination after maximal dilatation of the pupil; the lens is usually displaced upward and temporally. Other ocular findings in MFS include a flat cornea, retinal detachment, glaucoma, and early cataract formation.[49]

Dural ectasia results from enlargement of the spinal canal secondary to vertebral bone enlargement, most commonly in the lumbosacral region.[50] Dural ectasia is also seen in LDS and SGS and the vascular form of Ehlers-Danlos syndrome. It is present in more than two-thirds of patients with MFS and commonly presents with pain.[51] Pain may be associated with periosteal pressure, erosion of lumbosacral elements, traction of the nerve roots, or sacral microfractures secondary to osteopenia. A mouse model of MFS revealed higher dural levels of TGF-ß caused by fibrillin-1 deficiency.[52] These changes increase the risk of surgical complications, including spinal fracture and dural injury.

Patients with MFS develop lung bullae secondary to emphysematous pulmonary changes predominantly in the upper lobes, predisposing them to spontaneous pneumothorax. Patients may exhibit skin striae or striae atrophicae in MFS, owing to the disease as long as they are not associated with pronounced weight loss or pregnancy. Recurrent or incisional hernia and a high-arched palate may occur but are not included in the systemic score since these features are clinically nonspecific.[53]

Evaluation

In 1996, criteria for diagnosing MFS, known as Ghent nosology, were originally proposed. These criteria relied on major and minor clinical manifestations of the syndrome. Aortic root dilatation and ectopia lentis are cardinal features of the disease, and other systemic features involving the skeletal and cardiovascular organ systems and ocular and vertebral anomalies support the diagnosis. Major criteria included ectopia lentis, aortic root dilatation involving the sinuses of Valsalva or aortic dissection, and lumbosacral dural ectasia by computed tomography or magnetic resonance imaging, family or genetic history, and 4 of 8 typical skeletal manifestations. These criteria underwent revision in 2010 due to various limitations, including insufficient validation, limited applicability to children, and an inability to exclude syndromes such as LDS and SGS. The 2010 revised Ghent nosology puts greater weight on aortic root dilatation/dissection and ectopia lentis as the cardinal clinical features of MFS and testing for mutations in FBN1.[53]

Systemic Score

The revised Ghent nosology includes the following scoring system for systemic features:

  • Wrist and thumb sign: 3 points
  • Wrist or thumb sign: 1 point
  • Pectus carinatum deformity: 2 points
  • Pectus excavatum or chest asymmetry: 1 point
  • Hindfoot deformity: 2 points
  • Plain pes planus: 1 point
  • Pneumothorax: 2 points
  • Dural ectasia: 2 points
  • Protrusio acetabuli: 2 points
  • Reduced upper segment/lower segment ratio and increased arm span/height and no severe scoliosis: 1 point
  • Scoliosis or thoracolumbar kyphosis: 1 point
  • Reduced elbow extension (equal to 170 degrees with full extension): 1 point
  • At a minimum, 3 of the following 5 features: Dolichocephaly (reduced cephalic index or head width/length ratio), enophthalmos, down-slanting palpebral fissures, malar hypoplasia, retrognathia): 1 point
  • Skin striae: 1 point
  • Myopia greater than 3 diopters: 1 point
  • Mitral valve prolapse: 1 point
  • A systemic score equal to 7 indicates significant systemic involvement.[53] 

In patients with no family history of MFS, the presence of 1 of any of the following criteria is diagnostic for MFS:

  • Aortic criterion (aortic root dissection or diameter Z equal to 2) and ectopia lentis*
  • Aortic criterion (aortic root dissection or diameter Z equal to 2) and a causal FBN1 mutation
  • Aortic criterion (aortic diameter Z equal to 2 or aortic root dissection) and a systemic score equal to 7*
  • Ectopia lentis and an identified causal FBN1 mutation in an individual with an aortic aneurysm

In patients with a family history of MFS, the presence of 1 of any of the following criteria is diagnostic for MFS:

  • Ectopia lentis
  • A systemic score equal to  7 points*
  • Aortic criterion (aortic diameter Z equal to 3 below 20 years old, Z equal to 2 above 20 years, or aortic root dissection)*

For criteria with an asterisk (*), the diagnosis of MFS can be made only in the absence of discriminating features of Shprintzen-Goldberg syndrome, Loeys-Dietz syndrome, or vascular Ehlers-Danlos syndrome and after TGFBR1/2, collagen biochemistry, or COL3A1 testing if indicated. Later data suggest that additional gene mutations, including those in SMAD3, TGFB2, and SKI, should also be excluded.

The revised Ghent nosology recommends the following categories for individuals younger than 20 years old with features of MFS who do not meet diagnostic criteria for MFS:

  • Nonspecific connective tissue disorder applies if the systemic score is less than 7 or aortic root measurements are borderline (Z less than 3) without an FBN1 mutation.
  • Potential MFS applies if an FBN1 mutation is identified in a sporadic or familial case but the aortic root Z-score is less than 3.[53] 

Treatment / Management

Beta-blockers, noninvasive monitoring, restriction of vigorous physical exercise, and elective repair of the aorta have a greatly improved prognosis. In 1968, Bentall and De Bono introduced the Bentall procedure as the standard surgical approach for patients with MFS. A polyethylene conduit is attached to a mechanical aortic valve, replacing the dilated ascending aorta and aortic root.[54] Both coronary arteries are then reimplanted. Multicenter studies documented an early mortality rate of 1.5% and a survival rate of 84% at 5 years, 75% at 10 years, and 59% at 20 years. Rates of thromboembolism and endocarditis at 20 years have been 7% and 10%, respectively.[55] The mean age of surgery is 32; mechanical aortic valves are the preferred device due to their longevity.(B2)

Patients require lifelong anticoagulation secondary to mechanical valve replacement. For patients in whom anticoagulation is not recommended, valve-sparing techniques have been adopted, including the Yacoub technique and the valve reimplantation or David technique. With the Yacoub technique, the sinuses of Valsalva undergo resection and replacement with a vascular graft and coronary artery reimplantation; optimal patients have sinus or aortic dilation without annular dilation. The David technique involves reimplanting the native aortic valve into the graft for patients with annular involvement.[56] Twenty-five percent of patients with MFS undergoing valve-sparing procedures have aortic regurgitation at 10 years, secondary to disease progression. Valve-sparing procedures have lower operative mortality than the Bentall procedure at 5 years, 89% vs. 96%, and reduced incidence of reoperation at 5 years, 92% vs. 84%.[57](B2)

The 2010 ACC/AHA/AATS guidelines for thoracic aortic disease include recommendations for MFS. Patients should have echocardiography performed at the time of diagnosis and 6 months later to determine aortic root and ascending aortic diameters and their growth rate.[31] Regular aortic diameter monitoring is recommended for patients at risk for aortic dissection using computed tomography (CT), transthoracic echocardiography, and magnetic resonance imaging (MRI) to identify patients at risk for aortic dissection.[58] These imaging modalities provide information on the classification, origin, and extent of dissection, potential areas of hemorrhage, and other sequelae. Spiral CT angiography is the most frequently used modality worldwide for diagnosing TAAs and the degree of aneurysmal dilatation. CT limitations include aortic artifacts secondary to cardiac motion and implanted devices. Iodinated contrast-induced nephropathy can also occur in selected patients, and the use of repeated episodes of ionizing radiation exposure should be weighed in pediatric patients who require multiple scans in their lifetime. A Z-score, which designates a number of standard deviations from the mean for appropriate age and size matched with the normal population, should be used to monitor aortic diameter via CT scan serially. MRI is an alternative to CT in stable patients with suspected thoracic aortic disease, providing information on aortic morphology, ventricular dimension and function, and valvular regurgitation. MRI also allows monitoring of systemic manifestations of MFS, including dural ectasia, scoliosis, chest deformities, and protrusio acetabuli.(B3)

Transthoracic echocardiography is the primary modality in diagnosing MFS. However, transesophageal echocardiography is utilized in suspected dissection situations to measure the aortic root's maximal dimension with the parasternal long-axis view. The leading-edge-to-leading-edge technique in diastole is implemented in adults, while the inner-edge-to-inner-edge technique in systole is utilized among pediatric cardiologists. For MFS, aortic diameter at the sinuses of Valsalva is the key measurement since this is at greatest risk for aortic dissection, and monitoring is via echocardiography. A greater length of aortic dilation is associated with a worse prognosis.[59] Aortic root measurements should be parallel to the plane of the aortic valve and perpendicular to the axis of blood flow in the end-diastole.

In a retrospective analysis of 140 patients with MFS with FBN1 mutations who had undergone routine thoracoabdominal CT or MRI as part of their follow-up, about one-third had incidental findings of peripheral vascular aneurysms, with 55% of these patients requiring intervention.[60] Another prospective series systematically examined the supra-aortic trunks, the arteries of the upper and lower extremities, the aortoiliac arteries, and the visceral branches of the abdominal aorta in 21 patients with MFS. Ten (67%) had peripheral vascular arterial aneurysms, and 2 patients underwent semi-urgent repair.[61](B3)

When ascending aortic dimensions are stable, and there is no identified aortic disease, cross-sectional imaging is repeated every 3 to 5 years before elective operation and annually if the aortic diameter is less than 45 mm. However, if the aortic diameter is 45 mm or enlarges, more frequent imaging is suggested, up to twice annually, and may indicate the need for surgery. More frequent imaging is also prudent if the aortic diameter shows a rapid change (equal to 0.5 cm per year) or if the heart or valve function is circumspect.[53] In the pediatric population with MFS, annual imaging is recommended if the aortic size is stable and not markedly enlarged. Since no validated age-specific aortic diameters can be used to determine imaging intervals, aortic measurement comparisons should use body surface area. Individuals under 20 years of age with systemic findings suggestive of MFS should have annual echocardiograms due to the potential risk of aortic disease.[53]

As noted in the 2010 American College of Cardiology/American Heart Association/American Association for Thoracic Surgery (ACC/AHA/AATS) thoracic aorta guidelines, beta-blockers are recommended in adults with MFS and aortic aneurysm to lower the rate of aortic dilatation.[31] Beta-blockers decrease myocardial contractility and pulse pressure and may improve the elastic properties of the aorta in patients with an aortic root diameter of less than 40 mm.[62] Medication is recommended in patients with aortic root enlargement, a family history of aortic root enlargement, or a mutation previously associated with aortic disease. Dosing adjustments should be made to maintain the heart rate after submaximal exercise to less than 100 beats/minute in adults and less than 110 beats/minute in children.[53] Although propranolol was the first beta-blocker demonstrated to slow aortic dilation, longer-acting agents such as atenolol and metoprolol are also options. Labetalol is used among pregnant women because atenolol may impair fetal growth.(B2)

Beta-blocker therapy is also recommended for children with MFS and aortic aneurysm, though data in children is inconclusive. In an observational study, 44 children and adolescents with MFS were followed for almost 4 years.[63] The 20 patients on beta-blocker therapy and the 6 patients taking a calcium channel blocker had a slower absolute aortic growth rate. In a retrospective study of 63 children that compared beta-blocker therapy to no therapy,[64] there was no significant variation in the rate of change in aortic root measurements between the 2 groups at the study's end, and there were more side effects in treated patients.(B2)

While data are limited, adding an angiotensin 2 receptor blocker as tolerated to beta-blocker therapy may slow the rate of aortic root dilation in patients with MFS, as evidenced in the 2010 ACC/AHA/AATS guidelines. Renin-angiotensin system blockers may alleviate the clinical manifestations of MFS by blocking TGF-beta signaling.[26] The beneficial effects of angiotensin-converting enzyme (ACE) inhibitors in MFS are attributed to central blood pressure control and the reduction of aortic wall stiffness.[65] In a 2005 nonrandomized study, patients with MFS treated with ACE inhibition showed improved outcomes regarding aortic growth rate compared to those treated with beta-adrenergic blocker therapy over 3 years.[27] Angiotensin 2 stimulates the proliferation of smooth muscle cells, increases fibrosis, attenuates the expression of MMP-2 and MMP-9, and reduces apoptosis through binding to the angiotensin type 1 (AT1) receptors in the aortic wall. Data from animal models suggest that AT1 receptor antagonists reduce TGF-beta levels and can prevent the pathogenesis of MFS. Chiu et al.[66] have shown that losartan, in combination with beta-blockade, slows the progression of aortic root dilation more than beta-blockade alone in patients with MFS. Groenink et al.[67] provided additional evidence in the adult MFS population that losartan delays aortic root dilation of a native aortic root and decreases aortic arch dilation in a patient with prior aortic root replacement.(A1)

A randomized trial comparing losartan with atenolol in 608 children and adults with MFS and aortic Z-scores greater than 3.0 found no significant difference in the rate of aortic root dilation between the 2 treatment groups over 3 years.[68] Both treatments showed a comparable and significant decline in aortic root dilation relative to body surface area. The 3-year rates of aortic root surgery, aortic dissection, and death were similar in the losartan and atenolol treatment groups. There is scant evidence regarding the efficacy of ACE inhibitor therapy in patients with MFS.[69] A small randomized trial comparing perindopril with placebo (in addition to standard beta-blocker therapy) was retracted.[70] Although no other drug therapy has been officially established, statins may attenuate aortic root dilation in a mouse model of MFS by reducing the activity of vascular smooth muscle cells in the Marfan aorta.[71](A1)

Both animal and human data suggest that calcium channel blocker therapy may increase the risk of aortic complications. Marfan mice treated with calcium channel blockers demonstrated aneurysm expansion, rupture, and premature death. Patients with MFS and other forms of thoracic aortic aneurysm taking calcium channel blockers have an increased risk of aortic dissection and the need for aortic surgery.[72] An American Heart Association expert panel recommends low to moderate-intensity exercise (approximately 4 to 6 metabolic equivalents) for most patients with MFS. However, those with aortic root or valve replacement may tolerate less.[73] Patients with MFS should avoid contact sports, exercise to exhaustion, and isometric activities, including the Valsalva maneuver.[53](A1)

Elective replacement of aortic root disease in advance of critical enlargement is integral, as illustrated in a series of 675 patients with MFS from Johns Hopkins in which the 30-day mortality for elective, urgent (within 7 days of surgical consultation), or emergency repair (within 24 hours of consultation) was 1.5%, 2.6%, and 11.7%, respectively.[74] In another review, the actuarial survival at 5, 10, and 20 years of 231 patients who underwent elective aortic root replacement at Johns Hopkins was 88%, 81%, and 75%, respectively.[75] The 2010 ACC/AHA/AATS guidelines recommend an elective operation for patients with MFS at an external diameter of equal to 50 mm to avoid acute dissection or rupture.[31] Indications for surgical repair at an external diameter less than 50 mm include rapid growth (greater than 5 mm per year), family history of an aortic dissection at a diameter less than 50 mm, or progressive aortic valve regurgitation. The guidelines indicate that surgical repair is appropriate if the maximal cross-sectional area (square centimeters) of the ascending aorta or root divided by the patient's height in meters is greater than 10.[76] In the pediatric population, dissection is rare; therefore, surgical indications include aneurysms that show rapid enlargement (greater than 10 mm per year) and progressive aortic insufficiency.[77](B2)

There is conflicting data on the safety profile of pregnant women with MFS. The 2010 thoracic aortic disease guidelines urge pregnancy avoidance if the aortic root diameter exceeds 40 mm and further recommend prophylactic aortic root replacement in women who attempt pregnancy. The European and Canadian guidelines report an aortic root diameter of 45 mm to be considered safe. In a 2012 study, there was a significantly higher rate of aortic growth documented during pregnancy than at baseline.[78] In previously pregnant women, adverse outcomes and elective aortic surgery during long-term follow-up were more common than in women who remained childless. In women devoid of cardiac complications with MFS, pregnancy is well tolerated up to an aortic root diameter of 45 mm with proper clinical care. In the same vein, pregnancy should be strongly discouraged in women with a history of aortic dissection secondary to the high risk of aortic complications.[79](B2)

Differential Diagnosis

While assessing a patient with MFS, the following differential diagnoses should be considered:

  • LDS
  • SGS
  • Mitral valve prolapse syndrome
  • Congenital contractural arachnodactyly
  • Weill-Marchesani syndrome  
  • Ectopia lentis syndrome
  • Familial thoracic aortic aneurysm and dissection syndrome
  • Familial thoracic aortic aneurysm and dissection syndrome with bicuspid aortic valve
  • Familial thoracic aortic aneurysm and dissection syndrome with patent ductus arteriosus
  • Homocystinuria
  • Arterial tortuosity syndrome
  • Ehlers-Danlos syndrome (vascular type)
  • Ehlers-Danlos syndrome (cardiac valvular subtype)
  • Stickler syndrome (hereditary arthro-ophthalmopathy)
  • Klinefelter syndrome
  • Congenital bicuspid aortic valve disease with associated aortopathy
  • Aortic coarctation with associated ascending aortic enlargement
  • Congenital bicuspid aortic valve disease with associated aortopathy
  • Aortic coarctation with associated ascending aortic enlargement
  • Familial thoracic aortic aneurysm or aortopathy

Prognosis

The lifespan of untreated patients with the classic MFS was approximately 32 years in 1972 but has markedly increased to 72 years in 1993.[80][81] Beta-blockers, noninvasive aortic imaging, and elective aortic root repair have all improved survival. Life expectancy is significantly lower in men than in women. Patient longevity is now almost similar to persons without MFS. However, cardiovascular impairment is still the most common cause of mortality, mainly because of sudden death in an undiagnosed patient and in a newly diagnosed patient whose disease process has worsened beyond the scope of medical or surgical cure.

Complications

MFS has multisystem complications, which include:

  • Aortic aneurysm and dissection
  • Mitral valve prolapse
  • Mitral regurgitation
  • Aortic regurgitation
  • Lens subluxation (ectopia lentis)
  • Cataract, glaucoma, and retinal detachment
  • Spontaneous pneumothorax
  • Inguinal hernias
  • Scoliosis

Consultations

Consultation with a cardiothoracic surgeon should be scheduled in patients whose aortic diameter is more than 4 cm. Genetic counselor consultation is also beneficial. Pregnant patients with MFS should consult a high-risk obstetrician. Ophthalmologic consultation is strongly considered in patients with cataracts, glaucoma, lens subluxation (ectopia lentis), and retinal detachment.

Deterrence and Patient Education

MFS may create a substantial mental and physical burden on the patient, with different areas of concern for each person. According to Rao et al,[82] in the United States, the quality of life of patients with MFS is lower than that of control subjects without the disease. Pain is 1 of the most common concerns for patients with MFS. A recent systematic review of the literature estimated that the prevalence of pain in these patients is 47% to 92%.[83] Adults with MFS report limited physical capacity, reduced endurance, and, ultimately, depression and anxiety. Through appropriate diagnosis and treatment, along with timely rehabilitation, patients are better able to lead productive lives. Optimal treatment of chronic pain in patients with MFS should be a focus of future research.

Pearls and Other Issues

Key facts to keep in mind about Marfan syndrome are as follows:

  1. A diagnosis of MFS is based on characteristic manifestations, particularly aortic root dilatation/dissection and ectopia lentis, skeletal findings, mitral valve prolapse, dural ectasia, pneumothorax, and skin striae.
  2. Over 90% of patients with MFS have had FBN1 mutations identified.
  3. Applying diagnostic criteria to individuals younger than 20 can be challenging because not all clinical features may manifest themselves.
  4. The aortic root Z-score is used to identify aortic dilatation associated with body size.
  5. First-degree relatives of patients with a gene mutation associated with aortic aneurysms or dissection (e.g., FBN1, TGFBR1, TGFBR2, COL3A1, ACTA2, MYH11) should undergo counseling, genetic testing, and potentially aortic imaging.[53]

Enhancing Healthcare Team Outcomes

MFS is a serious chronic disorder with no cure. A significant number of patients do develop life-threatening complications like aortic aneurysms and dissections, retinal detachment, aortic regurgitation, and pectus deformities. Management of MFS and its related complications involves an interprofessional team, including the patient's primary care provider, with appropriate referrals to a cardiologist, cardiothoracic surgeon, ophthalmologist, and orthopedics. Care coordination should occur between the different providers and the nurses taking care of these patients so that they can quickly report any potential complications. Pharmacists should be aware of medications that patients with MFS should avoid. Physical therapists should guide patients with MFS on appropriate exercise activities, which should not include high-intensity exercises. The key is close follow-up and monitoring for complications. The interprofessional team members should communicate with each other so that the patient is provided with the optimal standard of care treatment. The lifespan of untreated patients with the classic MFS was approximately 32 years in 1972 but has markedly increased to 72 years in 1993.[80][81] Beta-blockers, noninvasive aortic imaging, and elective aortic root repair have all improved survival. Life expectancy is significantly lower in men than in women.

References

[1]

Robinson PN, Arteaga-Solis E, Baldock C, Collod-Béroud G, Booms P, De Paepe A, Dietz HC, Guo G, Handford PA, Judge DP, Kielty CM, Loeys B, Milewicz DM, Ney A, Ramirez F, Reinhardt DP, Tiedemann K, Whiteman P, Godfrey M. The molecular genetics of Marfan syndrome and related disorders. Journal of medical genetics. 2006 Oct:43(10):769-87     [PubMed PMID: 16571647]

Level 3 (low-level) evidence

[2]

Judge DP, Dietz HC. Marfan's syndrome. Lancet (London, England). 2005 Dec 3:366(9501):1965-76     [PubMed PMID: 16325700]

Level 3 (low-level) evidence

[3]

Gould RA, Sinha R, Aziz H, Rouf R, Dietz HC 3rd, Judge DP, Butcher J. Multi-scale biomechanical remodeling in aging and genetic mutant murine mitral valve leaflets: insights into Marfan syndrome. PloS one. 2012:7(9):e44639. doi: 10.1371/journal.pone.0044639. Epub 2012 Sep 11     [PubMed PMID: 22984535]

Level 3 (low-level) evidence

[4]

Ammash NM,Sundt TM,Connolly HM, Marfan syndrome-diagnosis and management. Current problems in cardiology. 2008 Jan;     [PubMed PMID: 18155514]

[5]

Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Dietz H. FBN1-Related Marfan Syndrome. GeneReviews(®). 1993:():     [PubMed PMID: 20301510]

[6]

Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, Puffenberger EG, Hamosh A, Nanthakumar EJ, Curristin SM. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991 Jul 25:352(6333):337-9     [PubMed PMID: 1852208]

[7]

Demetracopoulos CA, Sponseller PD. Spinal deformities in Marfan syndrome. The Orthopedic clinics of North America. 2007 Oct:38(4):563-72, vii     [PubMed PMID: 17945136]

[8]

Murdoch JL,Walker BA,Halpern BL,Kuzma JW,McKusick VA, Life expectancy and causes of death in the Marfan syndrome. The New England journal of medicine. 1972 Apr 13;     [PubMed PMID: 5011789]

[9]

Sponseller PD, Hobbs W, Riley LH 3rd, Pyeritz RE. The thoracolumbar spine in Marfan syndrome. The Journal of bone and joint surgery. American volume. 1995 Jun:77(6):867-76     [PubMed PMID: 7782359]

[10]

Robins PR, Moe JH, Winter RB. Scoliosis in Marfan's syndrome. Its characteristics and results of treatment in thirty-five patients. The Journal of bone and joint surgery. American volume. 1975 Apr:57(3):358-68     [PubMed PMID: 1123390]

[11]

McKUSICK VA. The cardiovascular aspects of Marfan's syndrome: a heritable disorder of connective tissue. Circulation. 1955 Mar:11(3):321-42     [PubMed PMID: 14352380]

[12]

Taub CC, Stoler JM, Perez-Sanz T, Chu J, Isselbacher EM, Picard MH, Weyman AE. Mitral valve prolapse in Marfan syndrome: an old topic revisited. Echocardiography (Mount Kisco, N.Y.). 2009 Apr:26(4):357-64. doi: 10.1111/j.1540-8175.2008.00825.x. Epub 2008 Nov 24     [PubMed PMID: 19054044]

[13]

Maumenee IH. The eye in the Marfan syndrome. Birth defects original article series. 1982:18(6):515-24     [PubMed PMID: 6983370]

[14]

Sponseller PD, Erkula G, Skolasky RL, Venuti KD, Dietz HC 3rd. Improving clinical recognition of Marfan syndrome. The Journal of bone and joint surgery. American volume. 2010 Aug 4:92(9):1868-75. doi: 10.2106/JBJS.I.00892. Epub     [PubMed PMID: 20686061]

[15]

Child AH, Aragon-Martin JA, Sage K. Genetic testing in Marfan syndrome. British journal of hospital medicine (London, England : 2005). 2016 Jan:77(1):38-41. doi: 10.12968/hmed.2016.77.1.38. Epub     [PubMed PMID: 26903455]

[16]

Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. The New England journal of medicine. 1994 May 12:330(19):1335-41     [PubMed PMID: 8152445]

Level 1 (high-level) evidence

[17]

Hilhorst-Hofstee Y, Rijlaarsdam ME, Scholte AJ, Swart-van den Berg M, Versteegh MI, van der Schoot-van Velzen I, Schäbitz HJ, Bijlsma EK, Baars MJ, Kerstjens-Frederikse WS, Giltay JC, Hamel BC, Breuning MH, Pals G. The clinical spectrum of missense mutations of the first aspartic acid of cbEGF-like domains in fibrillin-1 including a recessive family. Human mutation. 2010 Dec:31(12):E1915-27. doi: 10.1002/humu.21372. Epub     [PubMed PMID: 20886638]

Level 3 (low-level) evidence

[18]

Sakai LY, Keene DR, Glanville RW, Bächinger HP. Purification and partial characterization of fibrillin, a cysteine-rich structural component of connective tissue microfibrils. The Journal of biological chemistry. 1991 Aug 5:266(22):14763-70     [PubMed PMID: 1860873]

[19]

Dietz HC, Ramirez F, Sakai LY. Marfan's syndrome and other microfibrillar diseases. Advances in human genetics. 1994:22():153-86     [PubMed PMID: 7762452]

Level 3 (low-level) evidence

[20]

Reinhardt DP, Keene DR, Corson GM, Pöschl E, Bächinger HP, Gambee JE, Sakai LY. Fibrillin-1: organization in microfibrils and structural properties. Journal of molecular biology. 1996 Apr 26:258(1):104-16     [PubMed PMID: 8613981]

[21]

Zhang H, Hu W, Ramirez F. Developmental expression of fibrillin genes suggests heterogeneity of extracellular microfibrils. The Journal of cell biology. 1995 May:129(4):1165-76     [PubMed PMID: 7744963]

Level 3 (low-level) evidence

[22]

LeMaire SA, Russell L. Epidemiology of thoracic aortic dissection. Nature reviews. Cardiology. 2011 Feb:8(2):103-13. doi: 10.1038/nrcardio.2010.187. Epub 2010 Dec 21     [PubMed PMID: 21173794]

[23]

Hoffjan S. Genetic dissection of marfan syndrome and related connective tissue disorders: an update 2012. Molecular syndromology. 2012 Aug:3(2):47-58. doi: 10.1159/000339441. Epub 2012 Jun 12     [PubMed PMID: 23326250]

[24]

Castellano JM, Kovacic JC, Sanz J, Fuster V. Are we ignoring the dilated thoracic aorta? Annals of the New York Academy of Sciences. 2012 Apr:1254():164-174. doi: 10.1111/j.1749-6632.2012.06493.x. Epub     [PubMed PMID: 22548582]

Level 3 (low-level) evidence

[25]

Bolar N, Van Laer L, Loeys BL. Marfan syndrome: from gene to therapy. Current opinion in pediatrics. 2012 Aug:24(4):498-504. doi: 10.1097/MOP.0b013e3283557d4c. Epub     [PubMed PMID: 22705998]

Level 3 (low-level) evidence

[26]

Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science (New York, N.Y.). 2006 Apr 7:312(5770):117-21     [PubMed PMID: 16601194]

Level 3 (low-level) evidence

[27]

Brooke BS, Habashi JP, Judge DP, Patel N, Loeys B, Dietz HC 3rd. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. The New England journal of medicine. 2008 Jun 26:358(26):2787-95. doi: 10.1056/NEJMoa0706585. Epub     [PubMed PMID: 18579813]

[28]

Schlatmann TJ, Becker AE. Histologic changes in the normal aging aorta: implications for dissecting aortic aneurysm. The American journal of cardiology. 1977 Jan:39(1):13-20     [PubMed PMID: 831420]

[29]

Schlatmann TJ, Becker AE. Pathogenesis of dissecting aneurysm of aorta. Comparative histopathologic study of significance of medial changes. The American journal of cardiology. 1977 Jan:39(1):21-6     [PubMed PMID: 831424]

Level 2 (mid-level) evidence

[30]

Collins MJ, Dev V, Strauss BH, Fedak PW, Butany J. Variation in the histopathological features of patients with ascending aortic aneurysms: a study of 111 surgically excised cases. Journal of clinical pathology. 2008 Apr:61(4):519-23     [PubMed PMID: 17938162]

Level 3 (low-level) evidence

[31]

Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM, American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, Society for Vascular Medicine. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010 Apr 6:121(13):e266-369. doi: 10.1161/CIR.0b013e3181d4739e. Epub 2010 Mar 16     [PubMed PMID: 20233780]

Level 3 (low-level) evidence

[32]

Januzzi JL, Isselbacher EM, Fattori R, Cooper JV, Smith DE, Fang J, Eagle KA, Mehta RH, Nienaber CA, Pape LA, International Registry of Aortic Dissection (IRAD). Characterizing the young patient with aortic dissection: results from the International Registry of Aortic Dissection (IRAD). Journal of the American College of Cardiology. 2004 Feb 18:43(4):665-9     [PubMed PMID: 14975480]

Level 2 (mid-level) evidence

[33]

Mehta RH, O'Gara PT, Bossone E, Nienaber CA, Myrmel T, Cooper JV, Smith DE, Armstrong WF, Isselbacher EM, Pape LA, Eagle KA, Gilon D, International Registry of Acute Aortic Dissection (IRAD) Investigators. Acute type A aortic dissection in the elderly: clinical characteristics, management, and outcomes in the current era. Journal of the American College of Cardiology. 2002 Aug 21:40(4):685-92     [PubMed PMID: 12204498]

[34]

Svensson LG, Adams DH, Bonow RO, Kouchoukos NT, Miller DC, O'Gara PT, Shahian DM, Schaff HV, Akins CW, Bavaria J, Blackstone EH, David TE, Desai ND, Dewey TM, D'Agostino RS, Gleason TG, Harrington KB, Kodali S, Kapadia S, Leon MB, Lima B, Lytle BW, Mack MJ, Reece TB, Reiss GR, Roselli E, Smith CR, Thourani VH, Tuzcu EM, Webb J, Williams MR. Aortic valve and ascending aorta guidelines for management and quality measures: executive summary. The Annals of thoracic surgery. 2013 Apr:95(4):1491-505. doi: 10.1016/j.athoracsur.2012.12.027. Epub 2013 Jan 2     [PubMed PMID: 23291103]

Level 2 (mid-level) evidence

[35]

Rybczynski M, Mir TS, Sheikhzadeh S, Bernhardt AM, Schad C, Treede H, Veldhoen S, Groene EF, Kühne K, Koschyk D, Robinson PN, Berger J, Reichenspurner H, Meinertz T, von Kodolitsch Y. Frequency and age-related course of mitral valve dysfunction in the Marfan syndrome. The American journal of cardiology. 2010 Oct 1:106(7):1048-53. doi: 10.1016/j.amjcard.2010.05.038. Epub     [PubMed PMID: 20854973]

[36]

Faivre L, Collod-Beroud G, Loeys BL, Child A, Binquet C, Gautier E, Callewaert B, Arbustini E, Mayer K, Arslan-Kirchner M, Kiotsekoglou A, Comeglio P, Marziliano N, Dietz HC, Halliday D, Beroud C, Bonithon-Kopp C, Claustres M, Muti C, Plauchu H, Robinson PN, Adès LC, Biggin A, Benetts B, Brett M, Holman KJ, De Backer J, Coucke P, Francke U, De Paepe A, Jondeau G, Boileau C. Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. American journal of human genetics. 2007 Sep:81(3):454-66     [PubMed PMID: 17701892]

Level 2 (mid-level) evidence

[37]

Roman MJ, Devereux RB, Kramer-Fox R, Spitzer MC. Comparison of cardiovascular and skeletal features of primary mitral valve prolapse and Marfan syndrome. The American journal of cardiology. 1989 Feb 1:63(5):317-21     [PubMed PMID: 2913733]

[38]

Moon J,Shin MS,Lee HJ,Chung WJ,Park CH,Park KY, Newly developed aortic dissection after aorta cannulation during mitral valve surgery in a patient with marfan syndrome. Korean circulation journal. 2012 Jun     [PubMed PMID: 22787478]

[39]

David TE, Armstrong S, McCrindle BW, Manlhiot C. Late outcomes of mitral valve repair for mitral regurgitation due to degenerative disease. Circulation. 2013 Apr 9:127(14):1485-92. doi: 10.1161/CIRCULATIONAHA.112.000699. Epub 2013 Mar 4     [PubMed PMID: 23459614]

[40]

Alpendurada F, Wong J, Kiotsekoglou A, Banya W, Child A, Prasad SK, Pennell DJ, Mohiaddin RH. Evidence for Marfan cardiomyopathy. European journal of heart failure. 2010 Oct:12(10):1085-91. doi: 10.1093/eurjhf/hfq127. Epub     [PubMed PMID: 20861133]

Level 2 (mid-level) evidence

[41]

Erkula G, Jones KB, Sponseller PD, Dietz HC, Pyeritz RE. Growth and maturation in Marfan syndrome. American journal of medical genetics. 2002 Apr 22:109(2):100-15     [PubMed PMID: 11977157]

[42]

Lindsey JM,Michelson JD,MacWilliams BA,Sponseller PD,Miller NH, The foot in Marfan syndrome: clinical findings and weight-distribution patterns. Journal of pediatric orthopedics. 1998 Nov-Dec     [PubMed PMID: 9821131]

[43]

Shirley ED, Sponseller PD. Marfan syndrome. The Journal of the American Academy of Orthopaedic Surgeons. 2009 Sep:17(9):572-81     [PubMed PMID: 19726741]

[44]

Gjolaj JP, Sponseller PD, Shah SA, Newton PO, Flynn JM, Neubauer PR, Marks MC, Bastrom TP. Spinal deformity correction in Marfan syndrome versus adolescent idiopathic scoliosis: learning from the differences. Spine. 2012 Aug 15:37(18):1558-65. doi: 10.1097/BRS.0b013e3182541af3. Epub     [PubMed PMID: 22426454]

Level 2 (mid-level) evidence

[45]

Jones KB, Erkula G, Sponseller PD, Dormans JP. Spine deformity correction in Marfan syndrome. Spine. 2002 Sep 15:27(18):2003-12     [PubMed PMID: 12634560]

Level 2 (mid-level) evidence

[46]

Liang W, Yu B, Wang Y, Li Z, Qiu G, Shen J, Zhang J. Comparison of posterior correction results between Marfan syndrome scoliosis and adolescent idiopathic scoliosis-a retrospective case-series study. Journal of orthopaedic surgery and research. 2015 May 21:10():73. doi: 10.1186/s13018-015-0210-z. Epub 2015 May 21     [PubMed PMID: 25990568]

Level 2 (mid-level) evidence

[47]

Thakkar SC, Foran JR, Mears SC, Sponseller PD. Protrusio acetabuli and total hip arthroplasty in patients with Marfan syndrome. The Journal of arthroplasty. 2012 May:27(5):776-82. doi: 10.1016/j.arth.2011.08.010. Epub 2011 Oct 4     [PubMed PMID: 21975190]

[48]

Tsipouras P, Del Mastro R, Sarfarazi M, Lee B, Vitale E, Child AH, Godfrey M, Devereux RB, Hewett D, Steinmann B. Genetic linkage of the Marfan syndrome, ectopia lentis, and congenital contractural arachnodactyly to the fibrillin genes on chromosomes 15 and 5. The International Marfan Syndrome Collaborative Study. The New England journal of medicine. 1992 Apr 2:326(14):905-9     [PubMed PMID: 1542340]

[49]

Heur M, Costin B, Crowe S, Grimm RA, Moran R, Svensson LG, Traboulsi EI. The value of keratometry and central corneal thickness measurements in the clinical diagnosis of Marfan syndrome. American journal of ophthalmology. 2008 Jun:145(6):997-1001. doi: 10.1016/j.ajo.2008.01.028. Epub 2008 Apr 18     [PubMed PMID: 18378212]

Level 2 (mid-level) evidence

[50]

Pyeritz RE, Fishman EK, Bernhardt BA, Siegelman SS. Dural ectasia is a common feature of the Marfan syndrome. American journal of human genetics. 1988 Nov:43(5):726-32     [PubMed PMID: 3189335]

[51]

Foran JR, Pyeritz RE, Dietz HC, Sponseller PD. Characterization of the symptoms associated with dural ectasia in the Marfan patient. American journal of medical genetics. Part A. 2005 Apr 1:134A(1):58-65     [PubMed PMID: 15690402]

[52]

Jones KB, Myers L, Judge DP, Kirby PA, Dietz HC, Sponseller PD. Toward an understanding of dural ectasia: a light microscopy study in a murine model of Marfan syndrome. Spine. 2005 Feb 1:30(3):291-3     [PubMed PMID: 15682009]

Level 3 (low-level) evidence

[53]

Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, Hilhorst-Hofstee Y, Jondeau G, Faivre L, Milewicz DM, Pyeritz RE, Sponseller PD, Wordsworth P, De Paepe AM. The revised Ghent nosology for the Marfan syndrome. Journal of medical genetics. 2010 Jul:47(7):476-85. doi: 10.1136/jmg.2009.072785. Epub     [PubMed PMID: 20591885]

[54]

Cameron DE, Alejo DE, Patel ND, Nwakanma LU, Weiss ES, Vricella LA, Dietz HC, Spevak PJ, Williams JA, Bethea BT, Fitton TP, Gott VL. Aortic root replacement in 372 Marfan patients: evolution of operative repair over 30 years. The Annals of thoracic surgery. 2009 May:87(5):1344-9; discussion 1349-50. doi: 10.1016/j.athoracsur.2009.01.073. Epub     [PubMed PMID: 19379862]

Level 2 (mid-level) evidence

[55]

Geisbuesch S, Schray D, Bischoff MS, Lin HM, Di Luozzo G, Griepp RB. Frequency of reoperations in patients with Marfan syndrome. The Annals of thoracic surgery. 2012 May:93(5):1496-501. doi: 10.1016/j.athoracsur.2011.12.068. Epub 2012 Mar 22     [PubMed PMID: 22443865]

Level 2 (mid-level) evidence

[56]

David TE, Armstrong S, Manlhiot C, McCrindle BW, Feindel CM. Long-term results of aortic root repair using the reimplantation technique. The Journal of thoracic and cardiovascular surgery. 2013 Mar:145(3 Suppl):S22-5. doi: 10.1016/j.jtcvs.2012.11.075. Epub 2012 Dec 20     [PubMed PMID: 23260437]

Level 2 (mid-level) evidence

[57]

Patel ND, Weiss ES, Alejo DE, Nwakanma LU, Williams JA, Dietz HC, Spevak PJ, Gott VL, Vricella LA, Cameron DE. Aortic root operations for Marfan syndrome: a comparison of the Bentall and valve-sparing procedures. The Annals of thoracic surgery. 2008 Jun:85(6):2003-10; discussion 2010-1. doi: 10.1016/j.athoracsur.2008.01.032. Epub     [PubMed PMID: 18498810]

Level 2 (mid-level) evidence

[58]

Alamri HS, Alotaiby M, Almoghairi A, El Oakley RM. Lessons from the SYNTAX trial. Journal of the Saudi Heart Association. 2010 Apr:22(2):35-41. doi: 10.1016/j.jsha.2010.02.003. Epub 2010 Feb 24     [PubMed PMID: 23960592]

[59]

Roman MJ,Rosen SE,Kramer-Fox R,Devereux RB, Prognostic significance of the pattern of aortic root dilation in the Marfan syndrome. Journal of the American College of Cardiology. 1993 Nov 1     [PubMed PMID: 8227807]

[60]

Yetman AT, Roosevelt GE, Veit N, Everitt MD. Distal aortic and peripheral arterial aneurysms in patients with Marfan syndrome. Journal of the American College of Cardiology. 2011 Dec 6:58(24):2544-5. doi: 10.1016/j.jacc.2011.09.024. Epub     [PubMed PMID: 22133857]

Level 3 (low-level) evidence

[61]

Gaertner S, Alembik Y, Cordeanu EM, Dollfus H, Lejay A, Chakfe N, Stephan D. Should we systematically screen for peripheral arterial aneurysms in all patients with Marfan syndrome? International journal of cardiology. 2014:172(1):e94-5. doi: 10.1016/j.ijcard.2013.12.131. Epub 2014 Jan 4     [PubMed PMID: 24433614]

Level 3 (low-level) evidence

[62]

Groenink M, de Roos A, Mulder BJ, Spaan JA, van der Wall EE. Changes in aortic distensibility and pulse wave velocity assessed with magnetic resonance imaging following beta-blocker therapy in the Marfan syndrome. The American journal of cardiology. 1998 Jul 15:82(2):203-8     [PubMed PMID: 9678292]

Level 2 (mid-level) evidence

[63]

Rossi-Foulkes R, Roman MJ, Rosen SE, Kramer-Fox R, Ehlers KH, O'Loughlin JE, Davis JG, Devereux RB. Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. The American journal of cardiology. 1999 May 1:83(9):1364-8     [PubMed PMID: 10235096]

[64]

Selamet Tierney ES, Feingold B, Printz BF, Park SC, Graham D, Kleinman CS, Mahnke CB, Timchak DM, Neches WH, Gersony WM. Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. The Journal of pediatrics. 2007 Jan:150(1):77-82     [PubMed PMID: 17188619]

Level 2 (mid-level) evidence

[65]

Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. The American journal of cardiology. 2005 May 1:95(9):1125-7     [PubMed PMID: 15842990]

[66]

Chiu HH, Wu MH, Wang JK, Lu CW, Chiu SN, Chen CA, Lin MT, Hu FC. Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clinic proceedings. 2013 Mar:88(3):271-6. doi: 10.1016/j.mayocp.2012.11.005. Epub 2013 Jan 12     [PubMed PMID: 23321647]

Level 3 (low-level) evidence

[67]

Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, Scholte AJ, van den Berg MP, Spijkerboer AM, Marquering HA, Zwinderman AH, Mulder BJ. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. European heart journal. 2013 Dec:34(45):3491-500. doi: 10.1093/eurheartj/eht334. Epub 2013 Sep 2     [PubMed PMID: 23999449]

Level 1 (high-level) evidence

[68]

Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, Pearson GD, Selamet Tierney ES, Levine JC, Atz AM, Benson DW, Braverman AC, Chen S, De Backer J, Gelb BD, Grossfeld PD, Klein GL, Lai WW, Liou A, Loeys BL, Markham LW, Olson AK, Paridon SM, Pemberton VL, Pierpont ME, Pyeritz RE, Radojewski E, Roman MJ, Sharkey AM, Stylianou MP, Wechsler SB, Young LT, Mahony L, Pediatric Heart Network Investigators. Atenolol versus losartan in children and young adults with Marfan's syndrome. The New England journal of medicine. 2014 Nov 27:371(22):2061-71. doi: 10.1056/NEJMoa1404731. Epub 2014 Nov 18     [PubMed PMID: 25405392]

Level 1 (high-level) evidence

[69]

Williams A, Kenny D, Wilson D, Fagenello G, Nelson M, Dunstan F, Cockcroft J, Stuart G, Fraser AG. Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome - a randomised, double-blind, crossover trial. European journal of clinical investigation. 2012 Aug:42(8):891-9. doi: 10.1111/j.1365-2362.2012.02668.x. Epub 2012 Apr 3     [PubMed PMID: 22471392]

Level 1 (high-level) evidence

[70]

. Notice of Retraction: Ahimastos AA, et al. Effect of Perindopril on Large Artery Stiffness and Aortic Root Diameter in Patients With Marfan Syndrome: A Randomized Controlled Trial. JAMA. 2007;298(13):1539-1547. JAMA. 2015 Dec 22-29:314(24):2692-3. doi: 10.1001/jama.2015.16678. Epub     [PubMed PMID: 26594834]

Level 1 (high-level) evidence

[71]

McLoughlin D, McGuinness J, Byrne J, Terzo E, Huuskonen V, McAllister H, Black A, Kearney S, Kay E, Hill AD, Dietz HC, Redmond JM. Pravastatin reduces Marfan aortic dilation. Circulation. 2011 Sep 13:124(11 Suppl):S168-73. doi: 10.1161/CIRCULATIONAHA.110.012187. Epub     [PubMed PMID: 21911808]

Level 3 (low-level) evidence

[72]

Doyle JJ, Doyle AJ, Wilson NK, Habashi JP, Bedja D, Whitworth RE, Lindsay ME, Schoenhoff F, Myers L, Huso N, Bachir S, Squires O, Rusholme B, Ehsan H, Huso D, Thomas CJ, Caulfield MJ, Van Eyk JE, Judge DP, Dietz HC, GenTAC Registry Consortium, MIBAVA Leducq Consortium. A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome. eLife. 2015 Oct 27:4():. pii: e08648. doi: 10.7554/eLife.08648. Epub 2015 Oct 27     [PubMed PMID: 26506064]

[73]

Maron BJ, Chaitman BR, Ackerman MJ, Bayés de Luna A, Corrado D, Crosson JE, Deal BJ, Driscoll DJ, Estes NA 3rd, Araújo CG, Liang DH, Mitten MJ, Myerburg RJ, Pelliccia A, Thompson PD, Towbin JA, Van Camp SP, Working Groups of the American Heart Association Committee on Exercise, Cardiac Rehabilitation, and Prevention, Councils on Clinical Cardiology and Cardiovascular Disease in the Young. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation. 2004 Jun 8:109(22):2807-16     [PubMed PMID: 15184297]

Level 1 (high-level) evidence

[74]

Gott VL, Greene PS, Alejo DE, Cameron DE, Naftel DC, Miller DC, Gillinov AM, Laschinger JC, Pyeritz RE. Replacement of the aortic root in patients with Marfan's syndrome. The New England journal of medicine. 1999 Apr 29:340(17):1307-13     [PubMed PMID: 10219065]

[75]

Gott VL. Antoine Marfan and his syndrome: one hundred years later. Maryland medical journal (Baltimore, Md. : 1985). 1998 Nov:47(5):247-52     [PubMed PMID: 9798380]

[76]

Svensson LG, Khitin L. Aortic cross-sectional area/height ratio timing of aortic surgery in asymptomatic patients with Marfan syndrome. The Journal of thoracic and cardiovascular surgery. 2002 Feb:123(2):360-1     [PubMed PMID: 11828302]

Level 2 (mid-level) evidence

[77]

Zanotti G, Vricella L, Cameron D. Thoracic aortic aneurysm syndrome in children. Seminars in thoracic and cardiovascular surgery. Pediatric cardiac surgery annual. 2008:():11-21. doi: 10.1053/j.pcsu.2008.01.005. Epub     [PubMed PMID: 18396220]

[78]

Donnelly RT, Pinto NM, Kocolas I, Yetman AT. The immediate and long-term impact of pregnancy on aortic growth rate and mortality in women with Marfan syndrome. Journal of the American College of Cardiology. 2012 Jul 17:60(3):224-9. doi: 10.1016/j.jacc.2012.03.051. Epub     [PubMed PMID: 22789886]

Level 2 (mid-level) evidence

[79]

Tang GH, Malekan R, Lansman SL, Spielvogel D. Aortic valve-sparing reimplantation and mitral repair in a pregnant, second trimester Marfan patient: surgical decision. The Annals of thoracic surgery. 2013 Feb:95(2):701-3. doi: 10.1016/j.athoracsur.2012.06.049. Epub     [PubMed PMID: 23336884]

Level 3 (low-level) evidence

[80]

Finkbohner R, Johnston D, Crawford ES, Coselli J, Milewicz DM. Marfan syndrome. Long-term survival and complications after aortic aneurysm repair. Circulation. 1995 Feb 1:91(3):728-33     [PubMed PMID: 7828300]

[81]

Silverman DI, Burton KJ, Gray J, Bosner MS, Kouchoukos NT, Roman MJ, Boxer M, Devereux RB, Tsipouras P. Life expectancy in the Marfan syndrome. The American journal of cardiology. 1995 Jan 15:75(2):157-60     [PubMed PMID: 7810492]

[82]

Rao SS, Venuti KD, Dietz HC 3rd, Sponseller PD. Quantifying Health Status and Function in Marfan Syndrome. Journal of surgical orthopaedic advances. 2016 Spring:25(1):34-40     [PubMed PMID: 27082886]

Level 3 (low-level) evidence

[83]

Velvin G, Bathen T, Rand-Hendriksen S, Geirdal AØ. Systematic review of chronic pain in persons with Marfan syndrome. Clinical genetics. 2016 Jun:89(6):647-58. doi: 10.1111/cge.12699. Epub 2016 Jan 25     [PubMed PMID: 26607862]

Level 1 (high-level) evidence